Press Releases

WASHINGTON, D.C. – Reps. Earl L. “Buddy” Carter (R-GA), Scott Peters (D-CA), Nick Langworthy (R-NY), Mike Levin (D-CA), and Mike Carey (R-OH) introduced the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act to encourage innovative drug development targeting the most threatening infections, improve the appropriate use of antibiotics and antifungals, and ensure domestic availability of critical antimicrobials when needed.

 

“The United States leads the world in medical innovation, and we must ensure our policies reflect that. As a pharmacist, I’ve seen nothing short of miracles due to drug development in my lifetime, but we must continue to evolve to combat antimicrobial resistance,” said Rep. Carter. “The PASTEUR Act fosters collaboration between the public and private sectors to tackle market challenges in drug development, strengthen public health preparedness, and incentivize the development of new life-saving antibiotics.”  

 

“Antimicrobial resistance poses a growing and significant threat to Americans’ health. Almost 3 million Americans get sick with antibiotic resistant infections and nearly 35,000 die every year,” said Rep. Peters. “The PASTEUR Act will help us develop better antibiotics to counter resistant infections and help doctors ensure these drugs are used responsibly to stop the emergence of new superbugs. Congress must pass the PASTEUR Act and do everything in its power to prevent the next public health crisis."

 

“The PASTEUR Act is a monumental investment in bridging the gap between groundbreaking research and patient care, ensuring that cutting-edge science drives new antibiotic development while expanding affordable access for the public. By changing how critical antibiotics are paid for, the legislation ensures doctors and patients have reliable tools to fight dangerous infections and achieve better outcomes,” said Rep. Langworthy. “Affordable healthcare is a top priority, and legislation like the PASTEUR Act helps build long-term, sustainable solutions that strengthen our healthcare system, encourage responsible innovation, and protect patients now and in the future.”

 

“Antibiotic-resistant infections pose a serious and growing threat to millions of Americans, yet we continue to face critical gaps in our ability to bring new antimicrobials to market,” said Rep. Levin. “Right now, the incentives are backwards, making it harder to get new treatments into the hands of those who need them. The PASTEUR Act changes that equation with a smarter approach that pays for access rather than volume, while also supporting stewardship programs from hospitals to outpatient clinics. The pandemic showed us what happens when we're unprepared for health emergencies, and this legislation helps ensure we're ready for the next one. I thank Rep. Carter and Rep. Peters for leading this bipartisan legislation and I look forward to working together to get it done.”

 

“According to the Centers for Disease Control and Prevention, Americans suffer nearly 3 million antimicrobial-resistant infections annually, resulting in more than 35,000 deaths each year,” Rep. Carey said. “I’m proud to support the PASTEUR Act to help spur the development of innovative new treatments that will equip doctors with more tools to respond to, limit the spread of, and ultimately curb preventable deaths caused by breakthrough cases of infectious diseases.”

 

Antimicrobials – including antibiotics and antifungals – are medicines used to treat and prevent infections in humans, animals, and plants. Antimicrobial resistance (AMR) occurs when bacteria and fungi mutate and no longer respond to these medicines. As a result, treating infections becomes much harder, increasing the risk of disease spread, severe illness, and death. In the United States, more than 2.8 million antibiotic-resistant infections occur each year, resulting in over 35,000 deaths. A 2022 CDC special report found that the United States reversed its progress on AMR during the COVID-19 pandemic in 2020, and antimicrobial-resistant infections and deaths increased in hospitals by at least 15 percent. The estimated national cost to treat infections caused by the most common multidrug-resistant germs in health care is more than $4.6 billion annually, and recent analyses estimate that the broader impact of superbugs on the U.S. economy could reach tens of billions of dollars each year.

 

The AMR crisis has been further exacerbated by a lack of new drug development due to reduced economic incentives and challenging regulatory requirements, creating a severe market failure. In recent years, many of the innovative antibiotic companies working to develop new antimicrobials have filed for bankruptcy and stopped producing these innovative antibiotics completely.

 

The PASTEUR Act seeks to address this market failure and increase public health preparedness by keeping novel antimicrobials on the market and improving appropriate use across the health care system. While current contracts between the government and drug makers base payment on volume, the PASTEUR Act would establish a subscription-style model which would offer antibiotic developers predictable payments in exchange for access to their antibiotics, encouraging innovation and ensuring our health care system is prepared to treat resistant infections.

 

“bioMérieux enthusiastically supports the introduction of the PASTEUR Act and its recognition of the important role that diagnostics and antibiotic stewardship play in addressing antimicrobial resistance, along with the goal to develop new, novel antibiotics,” said Randy Pritchard, General Manager and Senior Vice President of Clinical Operations for bioMérieux North America. “Antimicrobial resistance is a growing problem in the U.S., leaving some infections difficult to treat or untreatable. This is why innovative, rapid, and accurate diagnostics are crucial in identifying infections and promoting better stewardship practices. The need for new therapies and proper utilization of fast, near-patient diagnostics for optimal actionability guiding treatment options will provide immediate benefit to patients today and in the future.”

 

“Infectious diseases physicians are on the front lines of the fight against antimicrobial resistance, and we urgently need the novel antibiotics and antifungals that the PASTEUR Act will deliver to save lives and to protect our ability to provide modern medical care like cancer chemotherapy, organ transplants, cesarean sections and hip and knee replacements. PASTEUR also makes crucial investments in antimicrobial stewardship to help ensure that antimicrobials are used wisely so patients can get the best possible outcomes. For the benefit of our patients, we call on Congress to advance this bipartisan bill swiftly,” said Ronald G. Nahass, MD, MHCM, FIDSA, President, Infectious Diseases Society of America.

 

"Legislative solutions to address threats posed by antimicrobial resistance (AMR) are imperative to our health and national security. We applaud the sponsors of the PASTEUR Act for their leadership. This bill will make much-needed, novel antibiotics a reality and fortify the health of Americans for future generations. The fight against AMR is not a partisan issue. We encourage broad support of the PASTEUR Act," said Candace DeMatteis, Vice President of Policy, Partnership to Fight Infectious Disease.

 

“As patients and caregivers, we see firsthand how antimicrobial resistance affects real lives, not just statistics. I’m encouraged that the PASTEUR Act recognizes patient outcomes and stewardship as essential measures of value. When treatments improve survival, reduce toxicity and side effects, and are easier to take, patients can actually complete therapy and recover. Embedding stewardship and appropriate use helps ensure these lifesaving medicines remain effective and accessible for the communities and patients who need them most,” said Rob Purdie, MyCARE Foundation.

 

“For people with cystic fibrosis, effective antibiotics are an essential lifeline. While antimicrobial resistance continues to pose an increasing and significant threat, the market is failing to develop new treatments patients need to survive,” said Mary Dwight, chief policy and advocacy officer at the Cystic Fibrosis Foundation. “The PASTEUR Act offers a smart, sustainable solution that rewards innovation while promoting responsible stewardship. For rare disease patients who are frequently exposed to resistant bacteria, PASTEUR helps ensure that a treatable infection does not become a terminal diagnosis.”

 

"The introduction of the PASTEUR Act of 2026 is a vital step forward in confronting one of the most urgent public health threats of our time. Antimicrobial resistance continues to claim millions of lives each year, and patients facing drug-resistant infections are left with fewer and fewer effective treatments," said John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO). "This updated PASTEUR legislation would help to repair the broken marketplace for antimicrobials by enabling a business model centered around the appropriate use of new and novel treatments to address the most threatening infections. We commend these bipartisan leaders in Congress for introducing this critical legislation for innovation and for working to ensure patients will have access to life-saving antimicrobials when they need them most."

 

 

Specifically, the PASTEUR Act would:

• Establish a Federal Subscription Model that provides annual payments to developers of eligible antibiotics and antifungals. Contract values range from $75 million to $300 million per year, with terms up to 10 years or until a generic or biosimilar enters the market. The annual predictable, set level of payment for a given product would be reduced by net revenues the manufacturer makes from its product each year, ensuring no more federal support is provided than necessary to provide a predictable return on investment.

 

• Use a Transparent Scoring System to determine eligibility and contract value, rewarding products that address urgent threats and unmet medical needs and that demonstrate major clinical and public health benefits.

 

• Establish a Critical Need Antimicrobial Advisory Group, consisting of infectious disease physicians, antimicrobial resistance and R&D experts, and patient advocates to guide the design of the program.

 

• Set Terms & Conditions of the subscription contracts that would require developers to ensure commercial availability, reliable supply, public reporting of resistance data, implementation of stewardship and education plans, adherence to manufacturing and environmental best practices, and completion of post-market studies. 

 

• Support Antimicrobial Stewardship and Surveillance by funding pilot programs for expanding stewardship efforts, including in outpatient settings (e.g. urgent care, retail clinics) and build on existing frameworks to enhance data collection on antibiotic use, resistance, and diagnostics through the CDC’s National Healthcare Safety Network and other surveillance systems.

 

Read the full bill text here.

 

A summary is available here.

###